Otros idiomas Corvus Pharmaceuticals, Inc.

Acciones

CRVS

US2210151005

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 30/04/2024			Varia. Cinco días.	Varia. 1 de enero.
1,55 ^USD	-1,90 %		+1,31 %	-11,93 %

09/04	Corvus Pharmaceuticals, Inc. anuncia el inicio de un ensayo clínico de fase 1 controlado con placebo de soquelitinib para la dermatitis atópica	CI
21/03	CORVUS PHARMACEUTICALS, INC. : El Oppenheimer continua con su recomendación de compra	ZM

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings	30/04
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis	09/04
Corvus Pharmaceuticals, Inc. Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis	09/04
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	20/03
Corvus Pharmaceuticals to Start Phase 1 Study of Atopic Dermatitis Treatment in Q2	19/03
Corvus: Q4 Earnings Snapshot	19/03
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	19/03
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	19/03
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024	13/03
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases	12/02
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data At the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases	12/02
Sector Update: Health Care Stocks Mixed in Afternoon Trading	09/02
Sector Update: Health Care Stocks Mixed Pre-Bell Friday	09/02
Corvus Pharmaceuticals Says Soquelitinib Received FDA Orphan Drug Designation	09/02
Corvus Pharmaceuticals Shares Rise on Orphan Drug Designation	08/02
Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma	08/02
Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer	06/02
Corvus Pharmaceuticals, Inc. Appoints Jeffrey Arcara as Chief Business Officer	06/02
Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell	23/01

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Corvus Pharmaceuticals, Inc.

Acciones

CRVS

US2210151005

Otros idiomas

Filtros